• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David Debono Details Anthem's Value-Based Strategy in Cancer Care

Video

Aligned with ASCO's Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care.

Aligned with the American Society of Clinical Oncology (ASCO)'s Patient-Centered Oncology Payment model, Anthem has launched its value-based strategy, called the oncology medical home, which seeks to promote quality metrics and improve outcome measures in cancer care, said David Debono, MD, medical director of Oncology at Anthem.

Transcript

AJMC®: How has the use of value-based models evolved in cancer care?

Dr Debono: Anthem has recently launched the value-based strategy that we're calling the oncology medical home. The oncology medical home is aligned with ASCO’s Patient-Centered Oncology Payment model. ASCO has gone to great lengths to really provide a guideline for payers and oncology practices on how best to execute value-based strategies.

Their Patient Centered Oncology Payment model centers on 4 components. The first component is what they call practice delivery requirements and we have called our core competencies. These are the type of care processes and comprehensive care that must be available to our members who are receiving oncology care, either within an oncology practice or a cancer center.

The second component of ASCO’s program is participation in a pathways program. We believe that our pathways program, again, is encouraging value-based strategies in oncology and ensuring high-quality care for our members.

The last 2 parts of ASCO’s model revolve around financial incentives for oncology practices. The first is a monthly care coordination fee, and Anthem has designed their monthly care coordination fee to be attributed to those members who are on outpatient chemotherapy or immunotherapy. We believe that the monthly care coordination fee will help support the practice, as they transform their care from a fee-for-service environment to a value-based environment.

The final component of ASCO’s model includes financial incentives for quality care and quality metrics. We have designed financial incentives to be associated with practices improving on quality metrics and improving on outcome measures. We believe that encouraging the improvement of these quality metrics will move the oncology practice toward a higher-value care, without compromising on the exciting modern therapies of precision medicine in oncology.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.